Skip to content
10-K

Annual Report

Astria Therapeutics, Inc.

0001410578-25-000309

← back to feed
Filed
Mar 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 56.43M sh
Shares Diluted FY 2024 · Dec 31, 2024 56.16M sh
Shares Diluted FY 2024 · Dec 31, 2023 30.12M sh
Capex FY 2024 · Dec 31, 2024 $325K
Capex FY 2024 · Dec 31, 2023 $25K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$81.21M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$68.45M
Short Term Investments FY 2024 · Dec 31, 2024 $268.31M
Short Term Investments FY 2024 · Dec 31, 2023 $71M
Cash And Equivalents FY 2024 · Dec 31, 2024 $59.82M
Cash And Equivalents FY 2024 · Dec 31, 2023 $175.53M
Stockholders Equity FY 2024 · Dec 31, 2024 $319.26M
Stockholders Equity FY 2024 · Dec 31, 2023 $243.12M
Stockholders Equity FY 2024 · Dec 31, 2022 $221.22M
Current Liabilities FY 2024 · Dec 31, 2024 $19.13M
Current Liabilities FY 2024 · Dec 31, 2023 $11.55M
Total Liabilities FY 2024 · Dec 31, 2024 $23.1M
Total Liabilities FY 2024 · Dec 31, 2023 $11.55M
Current Assets FY 2024 · Dec 31, 2024 $334.64M
Current Assets FY 2024 · Dec 31, 2023 $250.94M
Total Assets FY 2024 · Dec 31, 2024 $342.36M
Total Assets FY 2024 · Dec 31, 2023 $254.67M
Eps Diluted FY 2024 · Dec 31, 2024 −$1.68
Eps Diluted FY 2024 · Dec 31, 2023 −$2.42
Eps Basic FY 2024 · Dec 31, 2024 −$1.68
Eps Basic FY 2024 · Dec 31, 2023 −$2.42
Sga Expense FY 2024 · Dec 31, 2024 $34.45M
Sga Expense FY 2024 · Dec 31, 2023 $25.7M
Net Income FY 2024 · Dec 31, 2024 −$94.26M
Net Income FY 2024 · Dec 31, 2023 −$72.89M
Operating Income FY 2024 · Dec 31, 2024 −$111.56M
Operating Income FY 2024 · Dec 31, 2023 −$83.03M